Payment overview · 2025
General Payments
$386.46
22 reported records · 9 companies
Healthcare provider profile · identity verified
John Byrd
Allopathic & Osteopathic Physicians|Internal Medicine · GRACEVILLE, FL · NPI 1073932828
Verified facts
What the public records show
CMS Open Payments records show John Byrd received $386.46 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.52 | 27.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.77 | 16.8% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $46.58 | 12.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.50 | 10.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.92 | 10.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.22 | 7.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.47 | 6.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.27 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.21 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.46 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.84 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.77 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $46.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.92 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 187 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
187 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 136 |
| Montelukast Sodium | Montelukast Sodium | 494 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 436 | 115 |
| Gabapentin | Gabapentin | 403 | 105 |
| Omeprazole | Omeprazole | 333 | 84 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 299 | 81 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 284 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 249 | 98 |
| Furosemide | Furosemide | 247 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 73 |
| Prednisone | Prednisone | 243 | 141 |
| Tramadol Hcl | Tramadol Hcl | 238 | 86 |
| Celecoxib | Celecoxib | 236 | 57 |
| Meloxicam | Meloxicam | 213 | 75 |
| Metformin Hcl Er | Metformin Hcl | 209 | 57 |
| Farxiga | Dapagliflozin Propanediol | 187 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 57 |
| Potassium Chloride | Potassium Chloride | 181 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 36 |
| Losartan Potassium | Losartan Potassium | 167 | 56 |
| Simvastatin | Simvastatin | 164 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 162 | 57 |
| Bupropion Xl | Bupropion Hcl | 159 | 42 |
| Famotidine | Famotidine | 151 | 45 |
| Carvedilol | Carvedilol | 147 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 35 |
| Metformin Hcl | Metformin Hcl | 133 | 32 |
| Trazodone Hcl | Trazodone Hcl | 132 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 28 |
| Glipizide Er | Glipizide | 129 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 36 |
| Azelastine Hcl | Azelastine Hcl | 121 | 61 |
| Ozempic | Semaglutide | 115 | 20 |
| Azithromycin | Azithromycin | 113 | 76 |
| Lisinopril | Lisinopril | 108 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 26 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 104 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 45 |
| Fluconazole | Fluconazole | 99 | 48 |
| Cefdinir | Cefdinir | 94 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 26 |
| Allopurinol | Allopurinol | 91 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 22 |
| Midodrine Hcl | Midodrine Hcl | 78 | 14 |
| Mounjaro | Tirzepatide | 78 | 12 |
| Valsartan | Valsartan | 78 | 17 |
| Eliquis | Apixaban | 77 | 19 |
| Sucralfate | Sucralfate | 77 | 37 |
| Clonidine Hcl | Clonidine Hcl | 71 | 19 |
| Methocarbamol | Methocarbamol | 71 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 21 |
| Finasteride | Finasteride | 60 | 18 |
| Glyxambi | Empagliflozin/Linagliptin | 60 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 12 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Myrbetriq | Mirabegron | 57 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 15 |
| Sertraline Hcl | Sertraline Hcl | 56 | 18 |
| Baclofen | Baclofen | 55 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 43 |
| Spironolactone | Spironolactone | 55 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Nifedipine Er | Nifedipine | 53 | 12 |
| Amiloride Hcl | Amiloride Hcl | 52 | 20 |
| Mirtazapine | Mirtazapine | 52 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 19 |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Atenolol | Atenolol | 45 | 13 |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 16 |
| Dexamethasone | Dexamethasone | 44 | 34 |
| Topiramate | Topiramate | 44 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Mupirocin | Mupirocin | 37 | 26 |
| Nystatin | Nystatin | 37 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 26 |
| Estradiol | Estradiol | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 34 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 12 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 13 |
| Buspirone Hcl | Buspirone Hcl | 23 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Sulindac | Sulindac | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Lactulose | Lactulose | 22 | 13 |
| Roflumilast | Roflumilast | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 20 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Misoprostol | Misoprostol | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.46 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, EVENITY, FARXIGA, FUROSCIX, Ozempic, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error